|
News/ Information:
|
Important milestone achieved with oncology compounds: Progress of Boehringer Ingelheim's lead oncology compounds, BIBW 2992 and BIBF 1120 (Vargatef TM)
|
|---|---|
|
Website:
|
Further information |
Further progress in Oncology
Background information for medical media outside the US only
Information about cancer
Compound information
Further oncology information
Related Information
-
Prof. James Spicer
Senior Lecturer, Cancer Studies Division, King's College London, and Consultant in Medical Oncology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, UK
Prof. James Spicer is Senior Lecturer in the Cancer Studies Division of King's College London, and Honorary Consultant in Medical Oncology at Guy's and St Thomas' Foundation Hospital NHS Trust.
-
Dr. Rolf Kaiser
International Medical Project Leader for Phase I-III studies in Oncology, Boehringer Ingelheim, Biberach, Germany
Dr Rolf Kaiser has received several awards for teaching and research during his career, including the Antiemetic Research Award from the Multinational Association of Supportive Care in Cancer (MASCC) in 2003 for his work in exploring the role of pharmacogenetics in emesis. His research has been extensively published in a range of leading international peer-reviewed journals, including the Journal of Clinical Oncology and The Lancet Oncology.
-
Videos
-
-
Images: Further progress in Oncology
-
Signal Transduction: BIBW 2992 irreversibly block the growth factor receptor
-
Angiogenesis: Vessels invading the tumor transport oxigen and nutrition
-
Angiogenesis: Vessels invading the tumor transport oxigen and nutrition
-
Signal transduction: a ligand binds to a growth factor receptor and initiates growth signalling cascade
-
A tumor needs oxigen and nutrition to grow
-
The EGFR/Her2 Receptor Family
-
Laboratory work in Research and Development
-
R&D Laboratory Work
-
